X4 Pharmaceuticals Inc reports a Return on Equity (ROE) of -59.20%.

What is XFOR's dividend yield?

X4 Pharmaceuticals Inc offers a dividend yield of 0.00%.

What is XFOR's Quality Score?

Our AI rates XFOR's overall financial quality at 15 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy XFOR?

Our AI Timing Score for XFOR is 50 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does XFOR belong to?

X4 Pharmaceuticals Inc is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange

X4 Pharmaceuticals Inc (XFOR) Stock Price

Stock Check Daily update data at 8:30 AM
(Price: 2026-07-31 | FS: 2026-03-31)

XFOR AI Analysis Summary

Our AI summary for XFOR: X4 Pharmaceuticals Inc (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -59.20%, a dividend yield of 0.00%. Its financial Quality Score stands at 15/100 — fundamentals below the market average. The AI Timing Score is 50/100 — technical signals are mixed; watch for a clearer trend. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

XFOR

X4 Pharmaceuticals Inc

US:NASDAQ STOCK Healthcare >> Biotechnology News 99

USD 3.98

-0.02 (-0.50%) Day Change

Watchlist Portfolio Compare Chart

0.46

D/E

-59.2%

ROE

-36.9%

ROA

0.00%

Div Yield

X4 PHARMACEUTICALS INC
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 3.98 Price -0.02 (-0.50%) Day Change	NEWS SCORE: 99

XFOR, the overall quality is not good ( Quality = 15) and the timing to buy is ...(Sign In to See)...

Loading chart...

15 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
ROE is decreasing significantly
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...

Quality Factors

39%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	99
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	3.98
PBV / Sector	2.24 / 5.20
Earning Per Share	-1.05

PE / Sector	N/A / 19.97
PEG or PE/Growth / Sector	N/A / 1.22
Average 1M Daily Value	2.40 M GREAT
Average 1W Daily Value	2.38 M GREAT

Timing Factors

57%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

43%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

52%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	-1,106.30 / 98.71
NPM Average (%) / Sector	-932.15 / -1,721.76
NPM Change Average (%) / Sector	N/A / 5,211.62
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-36.90 / 27.02
ROA Average (%) / Sector	-43.75 / -368.17
ROA Change Average (%) / Sector	-1.74 / 5,404.12
ROE (%) / Sector	-59.20 / 3.47
ROE Average (%) / Sector	-119.11 / 6.51
ROE Change Average (%) / Sector	1.50 / 2,128.13
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -1.75

Registration Details

Analyze Date	2026-08-01 08:00:43
Symbol	XFOR
Name	X4 PHARMACEUTICALS INC
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	94.32 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	377.28 / 9,903.94

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 61 North Beacon Street, Boston, MA, United States, 02134

Phone: 857 529 8300

Website: https://www.x4pharma.com

Sector: Healthcare >> Biotechnology

Description: X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. It has a license agreement with Abbisko Therapeutics Co Ltd. to manufacture and distribute XOLREMDI in mainland China, Taiwan, Hong Kong and Macau; Norgine to develop, manufacture, and commercialize mavorixafor in Europe, Australia, and New Zealand; and Genzyme Corporation for CXCR4 receptor to develop and commercialize products containing licensed compounds for all therapeutic, prophylactic and diagnostic uses. The company is headquartered in Boston, Massachusetts.